Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Prostate-derived factor--a novel inhibitor of drug-induced cell death in colon cancer cells.

Proutski I, Stevenson L, Allen WL, McCulla A, Boyer J, McLean EG, Longley DB, Johnston PG.

Mol Cancer Ther. 2009 Sep;8(9):2566-74. doi: 10.1158/1535-7163.MCT-09-0158. Epub 2009 Sep 1.

2.

The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells.

Allen WL, McLean EG, Boyer J, McCulla A, Wilson PM, Coyle V, Longley DB, Casero RA Jr, Johnston PG.

Mol Cancer Ther. 2007 Jan;6(1):128-37.

3.

Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer.

Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C, Johnston PG.

Cancer Res. 2006 Mar 1;66(5):2765-77.

4.

Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.

Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG.

Clin Cancer Res. 2004 Mar 15;10(6):2158-67.

5.

Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.

Ward WH, Holdgate GA, Rowsell S, McLean EG, Pauptit RA, Clayton E, Nichols WW, Colls JG, Minshull CA, Jude DA, Mistry A, Timms D, Camble R, Hales NJ, Britton CJ, Taylor IW.

Biochemistry. 1999 Sep 21;38(38):12514-25.

PMID:
10493822

Supplemental Content

Loading ...
Support Center